293 related articles for article (PubMed ID: 25680761)
1. Patient preferences for a polypill for the prevention of cardiovascular diseases.
Laba TL; Howard K; Rose J; Peiris D; Redfern J; Usherwood T; Cass A; Patel A; Jan S
Ann Pharmacother; 2015 May; 49(5):528-39. PubMed ID: 25680761
[TBL] [Abstract][Full Text] [Related]
2. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.
Laba TL; Hayes A; Lo S; Peiris DP; Usherwood T; Hillis GS; Rafter N; Reid CM; Tonkin AM; Webster R; Neal BC; Cass A; Patel A; Rodgers A; Jan S
Med J Aust; 2014 Dec; 201(11):671-3. PubMed ID: 25495315
[TBL] [Abstract][Full Text] [Related]
3. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk.
Liu H; Patel A; Brown A; Eades S; Hayman N; Jan S; Ring I; Stewart G; Tonkin A; Weeramanthri T; Wade V; Rodgers A; Usherwood T; Neal B; Peiris D; Burke H; Reid C; Cass A; ; Kanyini GAP Study Team
BMC Public Health; 2010 Aug; 10():458. PubMed ID: 20687931
[TBL] [Abstract][Full Text] [Related]
5. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
6. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
[TBL] [Abstract][Full Text] [Related]
7. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
Trials; 2011 Jan; 12():3. PubMed ID: 21205325
[TBL] [Abstract][Full Text] [Related]
8. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
12. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
[TBL] [Abstract][Full Text] [Related]
13. The cardiovascular polypill: clinical data and ongoing studies.
Castellano JM; Bueno H; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391
[TBL] [Abstract][Full Text] [Related]
14. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
15. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
16. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
17. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.
Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S
Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629
[TBL] [Abstract][Full Text] [Related]
18. Could the polypill improve adherence? The patient perspective.
Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
[TBL] [Abstract][Full Text] [Related]
19. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
[TBL] [Abstract][Full Text] [Related]
20. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
